10:51 AM EST, 11/08/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) on Friday said new preclinical data from its BiSKIT (MDNA113) and IL-2 super agonist (MDNA11) programs will be presented today at the 39th Annual Meeting of Society for Immunotherapy of Cancer, being held in Houston, Texas. In addition, updated clinical results from the MDNA11 Phase 1/2 ABILITY-1 study will be presented Saturday Nov. 9, 2024 at the meet.
Price: 2.28, Change: -0.19, Percent Change: -7.69